DxS expands EGFR test license with Genzyme

DxS, a companion diagnostics firm based in the UK, has expanded its license with Genzyme Genetics, a business unit of US biotechnology major  Genzyme, for epidermal growth factor receptor, to include the USA and  Canada.

The license grants DxS the rights to develop and commercialize  diagnostic and research products that detect mutations in the EGFR gene  for non-small cell lung cancer, and sell them in these territories.

This builds on a license earlier this year in which Genzyme granted DxS  global EGFR rights with the exception of the USA, Canada, Mexico and  Hong Kong. Through an agreement in 2005 with the Massachusetts General  Hospital and the Dana Farber Cancer Institute, Genzyme holds the  exclusive worldwide diagnostic rights for use of the EGFR gene mutations  in testing for NSCLC tumors.